Get the Stockscreener App
1.62
6.36%
-0.11
After Hours:
1.62
Fortress Biotech Inc stock is traded at $1.62, with a volume of 457.69K.
It is down -6.36% in the last 24 hours and down -7.95% over the past month.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
See More
Previous Close:
$1.73
Open:
$1.75
24h Volume:
457.69K
Relative Volume:
0.97
Market Cap:
$44.72M
Revenue:
$80.97M
Net Income/Loss:
$-78.31M
P/E Ratio:
-0.1461
EPS:
-11.0849
Net Cash Flow:
$-129.56M
1W Performance:
+6.58%
1M Performance:
-7.95%
6M Performance:
-17.77%
1Y Performance:
-10.99%
1-Day Range:
$1.5805
$1.7595
1-Week Range:
$1.51
$1.805
52-Week Range:
$1.355
$2.89
Fortress Biotech Inc Stock (FBIO) Company Profile
Name
Fortress Biotech Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
1.62 | 44.72M | 80.97M | -78.31M | -129.56M | -11.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-24 | Resumed | ROTH MKM | Buy |
| Aug-04-22 | Initiated | Ladenburg Thalmann | Buy |
| Oct-02-20 | Initiated | The Benchmark Company | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Feb-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-22-17 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-16 | Initiated | ROTH Capital | Buy |
View All
Fortress Biotech Inc Stock (FBIO) Latest News
Equities Analysts Offer Predictions for FBIO Q1 Earnings - Defense World
Biotech Alert: Searches spiking for these stocks today - TipRanks
Fortress Biotech (NASDAQ:FBIO) Receives “Buy” Rating from Roth Mkm - Defense World
Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price - Simply Wall St
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma - Longview News-Journal
Lake Street Downgrades Checkpoint Therapeutics to Hold From Buy, $4.10 Price Target - Marketscreener.com
Checkpoint (CKPT) Shares Skyrocket After A Takeover Agreement - Stocks Telegraph
Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma -March 10, 2025 at 06:24 am EDT - Marketscreener.com
Sun Pharma to Acquire Checkpoint Therapeutics - StockTitan
Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -March 10, 2025 at 04:50 am EDT - Marketscreener.com
Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics for $355 million; shares edge higher - Mint
Sun Pharma to acquire US based onco-derma firm Checkpoint for $355 mn - Business Standard
Sun Pharma to acquire 100% stake in Nasdaq-listed Checkpoint Therapeutics - Business Standard
India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million - Reuters
India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million -March 09, 2025 at 11:49 pm EDT - Marketscreener.com
India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln By Investing.com - Investing.com Australia
Sun Pharma to acquire Checkpoint Therapeutics for Rs 3,000 crore - Business Upturn
Mustang Bio meets Nasdaq’s equity listing requirements By Investing.com - Investing.com South Africa
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement - The Manila Times
Fortress Biotech, Inc. (NASDAQ:FBIOP) Short Interest Down 78.3% in February - Defense World
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility - GlobeNewswire
Trading (FBIOP) With Integrated Risk Controls - Stock Traders Daily
FDA extends review of Fortress Biotech's CUTX-101 drug - MSN
Is Fortress Biotech Inc (NASDAQ: FBIO) Still Hot This Week? - Stocks Register
(FBIOP) On The My Stocks Page - Stock Traders Daily
Buying Buzz: Fortress Biotech Inc [FBIO] PRESIDENT, CEO & CHAIRMAN ROSENWALD LINDSAY A MD purchases 763,359 shares of the company – Knox Daily - Knox Daily
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement - The Manila Times
Nasdaq Compliance Alert: Mustang Bio Clears Major Hurdle with $2.5M Equity Milestone - StockTitan
Mustang Bio Closes $8 Million Public Offering - citybiz
Mustang Bio Announces Closing of $8 Million Public Offering - GlobeNewswire
Mustang Bio sets terms for $8M public offering - MSN
Mustang Bio sets terms for $8M public offering By Investing.com - Investing.com Nigeria
Mustang Bio Announces Pricing of $8 Million Public Offering - The Manila Times
Mustang Bio Announces Pricing of $8 Million Public Offering - Benzinga
Capital Raise Alert: Mustang Bio Secures Fresh $8M Funding Through Strategic Share & Warrant Offering - StockTitan
Fortress Biotech (NASDAQ:FBIOP) Trading Up 0.3% – Still a Buy? - Defense World
Mustang Bio stock plunges to 52-week low of $4 - MSN
Triplex vaccine enters Phase 2 trial in stem cell donors - MSN
Fortress Biotech announces first patient dosed in Phase 2 trial of Triplex - Yahoo Finance
Fortress Biotech Announces First Patient Dosed in Phase 2 - GlobeNewswire
Fortress Biotech (FBIO) Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination - StreetInsider.com
(FBIOP) Investment Analysis - Stock Traders Daily
FBIOFortress Biotech, Inc. Latest Stock News & Market Updates - StockTitan
Fortress Biotech, Inc. (NASDAQ:FBIO) Sees Large Increase in Short Interest - MarketBeat
Fortress Biotech (NASDAQ: FBIO) Receives Notification of Extended FDA Target Action Date for CUTX-101 - Defense World
Boom Or Bust: What Are Fortress Biotech Inc’s (NASDAQ:FBIO) Future Prospects? - Marketing Sentinel
FDA extends review of Fortress Biotech's CUTX-101 drug By Investing.com - Investing.com Canada
Fortress Biotech Inc Stock (FBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):